- Home
- QNST vs SLS Comparison
QNST vs SLS Comparison
Compare QNST & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNST | SLS |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.8M | 924.5M |
| IPO Year | 2009 | 2007 |
Fundamental Metrics
Financial Performance| Metric | QNST | SLS |
|---|---|---|
| Price | $16.75 | $12.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $24.75 | $10.00 |
| AVG Volume (30 Days) | 667.8K | ★ 10.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $282,140,000.00 | N/A |
| Revenue This Year | $18.59 | N/A |
| Revenue Next Year | $14.80 | $110.98 |
| P/E Ratio | $15.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.29 | $1.39 |
| 52 Week High | $17.13 | $15.88 |
Technical Indicators
Market Signals| Indicator | QNST | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 84.60 | 59.89 |
| Support Level | $13.56 | $3.91 |
| Resistance Level | N/A | $15.88 |
| Average True Range (ATR) | 0.60 | 1.66 |
| MACD | 0.29 | 0.06 |
| Stochastic Oscillator | 91.69 | 60.23 |
Price Performance
Historical ComparisonAbout QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.